Skip to main content

Table 3 Mean 2-hydroxybenzylamine pharmacokinetic parameters after oral doses

From: Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial

Parameter

2-Hydroxybenzylamine acetate dose

500 mg (n = 6)

750 mg (n = 5–6)

Day 1 (first dose)

Day 15 (last dose)

Day 1 (first dose)

Day 15 (last dose)

Ke

0.28 ± 0.04

0.22 ± 0.05

0.34 ± 0.06

0.22 ± 0.01

Half-life (h)

2.53 ± 0.39

3.27 ± 0.61

2.10 ± 0.45

3.12 ± 0.08

Vd/F

162 ± 21

183 ± 58

225 ± 79

264 ± 85

Cl/F

44.9 ± 6.3

38.2 ± 6.7

73.9 ± 18.5

58.9 ± 19.9

Tmax (h)

1.17 ± 0.68

0.83 ± 0.61

1.75 ± 1.25

2.00 ± 1.22

Cmax (ng/mL)

1955 ± 422

3177 ± 1993

1916 ± 524

2292 ± 913

Cavg (ng/mL)

817 ± 88

1133 ± 225

798 ± 193

1190 ± 455

Cmin (ng/mL)

285 ± 113

324 ± 50

261 ± 133

484 ± 287

PTF (%)

207 ± 67

237 ± 110

215 ± 87

158 ± 58

AUC0–8h (h·ng/mL)

6536 ± 701

9063 ± 1796

6385 ± 1547

9523 ± 3638

AUCinf (h·ng/mL)

7620 ± 1230

10,605 ± 1740

7186 ± 1780

11,746 ± 4602

Accumulation Index

 

1.38 ± 0.15

 

1.52 ± 0.27

  1. Ke, elimination rate constant; Vd/F, apparent volume of distribution; Cl/F, apparent clearance; Tmax, time to reach maximum plasma concentration; Cmax, maximum observed plasma concentration; Cavg, average observed plasma concentration; Cmin, minimum observed plasma concentration; PTF, peak-to-trough fluctuation; AUC0–8, area under the dosing interval curve; AUCinf, area under the concentration-time curve from zero to infinity.